Determination of Tamoxifen and its main metabolites in plasma samples from breast cancer patients by micellar liquid chromatography
Impacte
Scholar |
Altres documents de l'autoria: Vives-Peris, Vicente; Ochoa Aranda, Enrique; Bose, Devasish; Esteve-Romero, Josep
Metadades
Mostra el registre complet de l'elementcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/7013
comunitat-uji-handle3:10234/8638
comunitat-uji-handle4:
INVESTIGACIONAquest recurs és restringit
http://www.sciencedirect.com/science/article/pii/S0039914014006614 |
Metadades
Títol
Determination of Tamoxifen and its main metabolites in plasma samples from breast cancer patients by micellar liquid chromatographyData de publicació
2015-01Editor
ElsevierCita bibliogràfica
PERIS-VICENTE, Juan, et al. Determination of tamoxifen and its main metabolites in plasma samples from breast cancer patients by micellar liquid chromatography. Talanta, 2015, vol. 131, p. 535-540.Tipus de document
info:eu-repo/semantics/articleVersió de l'editorial
http://www.sciencedirect.com/science/article/pii/S0039914014006614Versió
info:eu-repo/semantics/publishedVersionParaules clau / Matèries
Resum
A method was developed for the analysis of tamoxifen and its main derivatives (4-hydroxytamoxifen, N–desmethyl-tamoxifen, tamoxifen-N-oxide and endoxifen) in human plasma, using micellar liquid chromatography coupled ... [+]
A method was developed for the analysis of tamoxifen and its main derivatives (4-hydroxytamoxifen, N–desmethyl-tamoxifen, tamoxifen-N-oxide and endoxifen) in human plasma, using micellar liquid chromatography coupled with fluorescence detection. Analytes were off-line derivatized by sample UV-irradiation for 20 min to form the photocycled fluorescent derivatives. Then samples were diluted, filtered and directly injected, thus avoiding extraction steps. The analytes were resolved using a mobile phase containing 0.08 M SDS-4.5% butanol at pH 3 running at 1.5 mL/min through a C18 column at 40 °C, without interferences from endogenous compounds in plasma. Excitation and emission wavelengths were 260 and 380 nm, respectively. The chromatographic analysis time was less than 40 min. The analytical methodology was validated following the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines in terms of: selectivity, linear range (0.3–15 μg/mL), linearity (r2>0.999), sensitivity (LOD, 65–80 ng/mL; LOQ, 165–200 ng/mL), intra- and interday accuracy (−12.2–11.5%) and precision (<9.2%) and robustness (<6.3%). The method was used to quantify the tamoxifen and tamoxifen derivatives in several breast cancer patients from a local hospital, in order to study the correlation between the genotype of the patient and the ability to metabolize tamoxifen. [-]
Publicat a
Talanta Volume 131, January 2015Drets d'accés
Copyright © 2014 Elsevier B.V. All rights reserved.
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
http://rightsstatements.org/vocab/InC/1.0/
info:eu-repo/semantics/restrictedAccess
Apareix a les col.leccions
- QFA_Articles [812]